Top

Published in:

01-12-2017 | Original Article

Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment

Authors: Philipp Mandel, Clemens Rosenbaum, Raisa S. Pompe, Thomas Steuber, Georg Salomon, Felix K. Chun, Markus Graefen, Hartwig Huland, Derya Tilki

Published in: World Journal of Urology | Issue 12/2017

Abstract

Purpose

This study aimed at analysing long-term oncologic outcomes in prostate cancer patients with limited nodal disease (1–2 positive lymph nodes) without adjuvant therapy after radical prostatectomy (RP).

Methods

We retrospectively analysed data of 209 pN1 patients who underwent RP between January 1998 and 2010 with one (160) or two (49) histologically proven positive lymph nodes (LNs) without adjuvant treatment. Biochemical recurrence-free survival, metastasis-free survival and cancer-specific survival (CSS) were reported. In multivariable regression analyses further prognosticators of oncologic outcome in these patients were analysed.

Results

Median follow-up was 60.2 months. There was no significant difference in oncologic outcome between patients with one and two positive LNs. 73.1% (76.7%) of patients with one (two) positive LNs had biochemical recurrence during the follow-up period, 20.0% (25.6%) developed metastasis and 8.1% (6.1%) died of their disease. The only factors significantly associated with oncologic outcome in multivariable analysis were Gleason score and pT-stage.

Conclusions

Patients with limited nodal disease (1–2 positive LNs) without adjuvant therapy showed favourable CSS-rates above 94% after 5 years. A subgroup of these patients (37%) remained metastasis-free without need of salvage treatment.

Available only for authorised users

Mottet N, Bellmunt J, Briers E et al (2016) Guidelines on prostate cancer 2016. European Association of Urology

Briganti A, Giannarini G, Karnes R et al (2015) What evidence do we need to support the use of extended pelvic lymph node dissection in prostate cancer? Eur Urol 67:597–598CrossRefPubMed

Briganti A, Abdollah F, Nini A et al (2012) Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 61:1132–1138CrossRefPubMed

Gakis G, Boorjian S, Briganti A et al (2014) The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 66:191–199CrossRefPubMed

Bivalacqua T, Pierorazio P, Gorin M et al (2013) Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. Urology 82:653–659CrossRefPubMedPubMedCentral

Verhagen P, Schröder F, Collette L et al (2010) Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol 58:261–269CrossRefPubMed

Briganti A, Karnes J, Da Pozzo L et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A newproposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55:261–270CrossRefPubMed

Boorjian S, Thompson R, Siddiqui S et al (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864–871CrossRefPubMed

Messing E, Manola J, Yao J et al (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472–479CrossRefPubMed

10.

Spiess P, Lee A, Busb J (2007) Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 99:321–325CrossRefPubMed

11.

Briganti A, Karnes R, Da Pozzo L et al (2011) Combination of adjuvant hormonal and radiation therapy Significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: results of a matched analysis. Eur Urol 59:832–840CrossRefPubMed

12.

Da Pozzo L, Cozzarini C, Briganti A et al (2009) Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 55:1003–1011CrossRefPubMed

13.

Abdollah F, Karnes R, Suardi N et al (2014) Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. JCO 32:3939–3947CrossRef

14.

Touijer K, Mazzola C, Sjoberg D et al (2014) Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65:20–25CrossRefPubMed

15.

Mandel P, Kriegmair MC, Bogdan K, Boehm K, Budäus L, Graefen M, Huland H, Tilki D (2016) Association between lymph node counts and oncological outcomes in lymph node positive prostate cancer. Eur Urol Focus. doi:10.1016/j.euf.2016.02.018 PubMed

16.

Sobin L, Gospodarowicz M, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, New York

17.

Seiler R, Studer U, Tschan K et al (2014) Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. J Urol 191:1280–1285CrossRefPubMed

18.

Bader P, Burkhard F, Markwalder R et al (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849–854CrossRefPubMed

19.

Mandel P, Weinhold P, Michl U et al (2015) Impact of prostate volume on oncologic, perioperative, and functional outcomes after radical prostatectomy. Prostate 75:1436–1446CrossRefPubMed

20.

Budaus L, Isbarn H, Schlomm T et al (2009) Current technique of open intrafascial nerve-sparing retropubic prostatectomy. Eur Urol 56:317–324CrossRefPubMed

21.

Gleason D, Mellinger G (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64CrossRefPubMed

22.

Sauter G, Steurer S, Clauditz TS, Krech T, Wittmer C, Lutz F, Lennartz M, Janssen T, Hakimi N, Simon R, von Petersdorff-Campen M, Jacobsen F, von Loga K, Wilczak W, Minner S, Tsourlakis MC, Chirico V, Haese A, Heinzer H, Beyer B, Graefen M, Michl U, Salomon G, Steuber T, Budäus LH, Hekeler E, Malsy-Mink J, Kutzera S, Fraune C, Göbel C, Huland H, Schlomm T (2016) Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol 69(4):592–598. doi:10.1016/j.eururo.2015.10.029 CrossRefPubMed

23.

Kim DK, Kyo CK, Raheem AA, Kim KH, Chung BH, Choi YD, Rha KH (2016) Single positive lymph node prostate cancer can be treated surgically without recurrence. PLoS One. doi:10.1371/journal.pone.0152391

24.

Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, Karnes RJ (2016) Natural history of clinical recurrence patterns of lymph node-positive prostate cancer after radical prostatectomy. Eur Urol 69(1):135–142. doi:10.1016/j.eururo.2015.03.036 CrossRefPubMed

25.

Han M, Partin A, Pound C et al (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 28:555–565CrossRefPubMed

Title: Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment
Authors: Philipp Mandel
Clemens Rosenbaum
Raisa S. Pompe
Thomas Steuber
Georg Salomon
Felix K. Chun
Markus Graefen
Hartwig Huland
Derya Tilki
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 12/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2079-4

At a glance: The STEP trials

Springer Medicine

Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2017

The suspension sutures during minimally invasive radical prostatectomy

‘Real-life experience’: recurrence rate at 3 years with Hexvix® photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC—a prospective controlled study

Knowledge, attitudes, and practices towards prostate cancer screening amongst men living in the southern Italian peninsula: the Prevention and Research in Oncology (PRO) non-profit Foundation experience

Influence of acetylsalicylic acid and low-molecular weight heparins on the formation of renal hematoma after shock wave lithotripsy

A prospective randomized comparison among SWL, PCNL and RIRS for lower calyceal stones less than 2 cm: a multicenter experience

Transperineal reanastomosis for treatment of highly recurrent anastomotic strictures after radical retropubic prostatectomy: extended follow-up